ESTUTC-5 New YorkLog in Sign up

VKTX
Viking Therapeutics, Inc
stockNASDAQ

Market OpenNov 10, 2026 1:46:22 PM EST

28.88USD-0.379%(-0.11)2,359,532

Pre-marketNov 10, 2026 9:27:30 AM EST

28.80USD-0.655%(-0.19)

28.82Bid29.59Ask0.77Spread

VKTX News

Day breaks

07:05 AM ESTViking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026 ·

PR Newswire

11:30 AM ESTHere's the 1 Stock I'd Most Want to Buy If the Market Crashes ·

The Motley Fool

07:15 AM ESTViking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. ·

The Motley Fool

04:00 AM ESTHow I'd Invest $10,000 Right Now ·

The Motley Fool+1 source

04:30 PM ESTViking Therapeutics to Participate at Upcoming Investor Conferences ·

PR Newswire

07:22 AM ESTUBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. ·

The Motley Fool+1 source

11:53 PM EDTViking (VKTX) Q3 2026 Earnings Call Transcript ·

The Motley Fool+1 source

08:51 PM EDTViking outlines ~$100M average quarterly cash usage as Phase III SUNRISE and VANQUISH advance ·

Seeking Alpha

08:50 PM EDTViking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript ·

Seeking Alpha

05:57 PM EDTViking Therapeutics Q3 Net Loss Widens to $183.2 Million ·

Securities.io

05:38 PM EDTEarnings call transcript: Viking Therapeutics Q3 2026 loss widens on higher R&D ·

Investing.com

05:12 PM EDTViking Therapeutics falls on third quarter loss miss ·

Investing.com

04:21 PM EDTViking Therapeutics GAAP EPS of -$1.55 misses by $0.50 ·

Seeking Alpha

04:05 PM EDTViking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update ·

PR Newswire

10:41 AM EDTViking Therapeutics earnings up next: Obesity drug progress in focus ·

Investing.com

10:21 AM EDTAfter Wegovy and Zepbound, 6 weight-loss drugs in development ·

Quartz

09:51 AM EDTViking Therapeutics stock hits 52-week low at 24.94 USD ·

Investing.com